𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Twenty-four-hour tremor recordings in the evaluation of the treatment of Parkinson's disease

✍ Scribed by E. Scholz; M. Bacher; H. C. Diener; J. Dichgans


Publisher
Springer
Year
1988
Tongue
English
Weight
737 KB
Volume
235
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

✦ Synopsis


A new method of prolonged recording of EMG provides a good estimate of spontaneous and induced diurnal variations in resting tremor in Parkinson's disease. It provides a record and a measure of the effects of treatment. Tremor intensity shows considerable variations even over short periods of time. Therefore short-term measurements of tremor are unhelpful. Long-term recordings agree better with the patient's assessment than with the clinical rating score. Repeated recordings over a similar 10-h period on 3 consecutive days in one patients showed fairly constant measures of occurrence and intensity of tremor. In contrast to accelerometer measurements of tremor, artefacts caused by movements and general activity of the patient do not materially interfere with tremor evaluation using surface EMG.


πŸ“œ SIMILAR VOLUMES


Evaluation of Parkinson's Disease in ent
✍ John M. Bertoni; Pamela M. Sprenkle; Daniel Strickland; Nancy Noedel πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 121 KB

## Abstract We examined a sample of individuals in the Nebraska State Parkinson's Disease Registry (NSPDR) to determine what proportion meets standard criteria for Parkinson's disease (PD). The NSPDR was established in 1996 in an effort to understand the high prevalence of PD in Nebraska. Only mini

Viral vectors in the treatment of Parkin
✍ David S. Latchman; Robert S. Coffin πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 2 views

s disease is an obvious target for the development of gene therapy procedures which could involve both the delivery of the gene encoding tyrosine hydroxylase to boost dopamine production or the delivery of genes encoding neurotrophic factors such as GDNF to promote the survival of dopaminergic neuro

Future directions in the treatment of Pa
✍ Anthony H.V. Schapira πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 75 KB

The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykine